Allogene Therapeutics
A clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
Allogene is developing a pipeline of “off-the-shelf” CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Latest Allogene Therapeutics News & Features
16 May 2024
22 September 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze